Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use.

ABSTRACT:

Background

The Oncotype DX breast recurrence score has been introduced more than a decade ago to aid physicians in determining the need for systemic adjuvant chemotherapy in patients with early-stage, estrogen receptor (ER)+, lymph node-negative breast cancer.

Methods

In this study, we utilized data from The Surveillance, Epidemiology, and End Results (SEER) Program to investigate temporal trends in Oncotype DX usage among US breast cancer patients in the first decade after the introduction of the Oncotype DX assay.

Results

We found that the use of Oncotype DX has steadily increased in the first decade of use and that this increase is associated with a decreased usage of chemotherapy. Patients who utilized the Oncotype DX test tended to have improved survival compared

SUBMITTER: Schaafsma E 

PROVIDER: S-EPMC8285794 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature